New therapies targeting triglyceride-rich lipoprotein metabolism reduce atherosclerosis in experimental models and TRL concentrations in patients, though clinical trials are still required.
Do therapies targeting TRL metabolism reduce atherosclerotic cardiovascular events in patients with elevated remnant cholesterol?
Emerging therapies targeting TRL metabolism, such as ANGPTL3 and ApoC-III inhibitors, show promise in reducing atherosclerosis and require further clinical trials to establish their role in cardiovascular risk management.
Emerging evidence suggests that elevated concentrations of triglyceride-rich lipoprotein remnants (TRLs) derived from hepatic and intestinal sources contribute to the risk of atherosclerotic cardiovascular events. Natural selection studies support a causal role for elevated concentrations of remnant cholesterol and the pathways contributing to perturbations in metabolic pathways regulating TRLs with an increased risk of atherosclerotic cardiovascular disease events. New therapies targeting select catalytic pathways in TRL metabolism reduce atherosclerosis in experimental models, and concentrations of TRLs in patients with a vast range of triglyceride levels. Clinical trials with inhibitors of angiopoietin-like 3 protein and apolipoprotein C-III will be required to provide further guidance on the potential contribution of these emerging therapies in the paradigm of cardiovascular risk management in patients with elevated remnant cholesterol. Keywords: angiopoietin-like 3 protein inhibitors, apolipoprotein C-III inhibitors, eicosapentaenoic acid, omega-3 fatty acids, triglyceride-rich lipoproteins, triglycerides
Rosenson et al. (Mon,) conducted a review in Elevated triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease. Therapies targeting triglyceride-rich lipoprotein metabolism (e.g., ANGPTL3 and ApoC-III inhibitors) was evaluated. New therapies targeting triglyceride-rich lipoprotein metabolism reduce atherosclerosis in experimental models and TRL concentrations in patients, though clinical trials are still required.